Dung T. Le
YOU?
Author Swipe
View article: 497 A mutant KRAS peptide vaccine (mKRAS-VAX) combined with immune checkpoint blockade recruits vaccine-induced T-cells into metastatic MMRp/MSS colorectal tumors
497 A mutant KRAS peptide vaccine (mKRAS-VAX) combined with immune checkpoint blockade recruits vaccine-induced T-cells into metastatic MMRp/MSS colorectal tumors Open
View article: Synthesis, Biological Evaluation, and Docking Study of Rhinacanthin-Related Derivatives as α-Glucosidase Inhibitors
Synthesis, Biological Evaluation, and Docking Study of Rhinacanthin-Related Derivatives as α-Glucosidase Inhibitors Open
This study describes the design, synthesis, and in vitro evaluation of 25 rhinacanthin-related derivatives as potential α-glucosidase inhibitors. The synthesized compounds were characterized using 1H and 13C NM…
View article: A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages
A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages Open
Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and myeloid-rich microenvironment that confer resistance to immunotherapies. Previous studies demonstrated that disrupting the immune-stroma CXCR4-CXCL12 axis facilit…
View article: Supplementary Figure 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Figure 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Figure 6. Validating the functional relevance of Th and Treg proximity.
View article: Supplementary Table 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 1. Antibodies Used for CyTOF Staining.
View article: PRCA-07 RISK FACTORS AND OVERALL SURVIVAL IN STAGE IV COLORECTAL CANCER PATIENTS WHO DEVELOP BRAIN METASTASIS: A POPULATION-BASED STUDY FROM 2013-2023
PRCA-07 RISK FACTORS AND OVERALL SURVIVAL IN STAGE IV COLORECTAL CANCER PATIENTS WHO DEVELOP BRAIN METASTASIS: A POPULATION-BASED STUDY FROM 2013-2023 Open
Colorectal cancer (CRC) is the third most common cancer globally. Though rare, brain metastasis (BM) in CRC patients significantly impacts morbidity and mortality. The incidence of BM is expected to rise due to improved screening and treat…
View article: Supplementary Table 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 3. Patient Characteristics by Metastasis Status.
View article: Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Figure 5. Best radiographic response to relatlimab and nivolumab in patients with microsatellite stable colorectal cancer stratified by pre-treatment cytotoxic T cell (A) and Treg (B) density.
View article: Supplementary Table 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 2. Antibodies Used for IMC Staining.
View article: Supplementary Table 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 6. Summary of All Grade 3 or Higher Adverse Events.
View article: Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Figure 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Figure 4. IMC analysis of TME.
View article: Supplementary Figure 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Figure 2 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Figure 2. Comparison of the tumor microenvironment (TME) of liver metastases across patients.
View article: Data from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Data from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Purpose:Combined inhibition of lymphocyte-activation gene 3 (LAG-3) and PD-1 improves outcomes in patients with melanoma. Increased LAG-3 expression in colorectal cancer correlates with reduced survival. Higher mucin and PD-L1 expression i…
View article: Supplementary Table 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 5. Summary of Grade 3 or Higher Adverse Events Attributed to Nivolumab and/or Relatlimab.
View article: Supplementary Figure 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Figure 3 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Figure 3. CyTOF analysis of circulating PBMCs.
View article: Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Figure 1. Comparison of the tumor microenvironment (TME) between colorectal cancer (CRC) liver and lung metastases.
View article: Supplementary Table 8 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 8 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 8. Programmed Death Ligand 1 (PD-L1) and Lymphocyte activation gene 3 (LAG-3) Immunohistochemistry.
View article: Supplementary Table 7 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 7 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 7. Summary of All Adverse Events Attributed to Nivolumab and/or Relatlimab.
View article: Supplementary Table 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Supplementary Table 4 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Supplementary Table 4. Representativeness of Study Participants.
View article: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer Open
Purpose: Combined inhibition of lymphocyte-activation gene 3 (LAG-3) and PD-1 improves outcomes in patients with melanoma. Increased LAG-3 expression in colorectal cancer correlates with reduced survival. Higher mucin and PD-L1 expression …
View article: Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly
Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly Open
Discovering the brakes/checkpoints that cancer places on the immune system to prevent being eradicated led to the 2018 Nobel Prize and the development of multiple Food and Drug Administration-approved immune checkpoint inhibitors (ICIs). I…
View article: Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting colony stimulating factor-1 receptor inhibitor IMC-CS4 in pancreatic adenocarcinoma
Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting colony stimulating factor-1 receptor inhibitor IMC-CS4 in pancreatic adenocarcinoma Open
Background: We previously reported increased M1/M2 ratio and decreased PDL1+ M2-like tumor associated macrophages (TAM) was associated with longer survival in pancreas adenocarcinoma (PDA). We hypothesized targeting M2-like macrophages, re…
View article: Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma
Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma Open
Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and resistant to immunotherapy. Although immune recognition can be enhanced with immunomodulatory agents including checkpoint inhibitors and vaccines, few patients experience clinica…
View article: Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors Open
Background Resistance to immune checkpoint inhibitors and targeted treatments for cancer is common; thus, novel immunotherapy agents are needed. Urelumab is a monoclonal antibody agonist that binds to CD137 receptors expressed on T cells. …
View article: Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032) Open
Background Pancreatic cancer is one of the deadliest cancer types and represents a major unmet medical need. CheckMate 032 investigated safety and efficacy of nivolumab monotherapy and nivolumab plus ipilimumab with/without cobimetinib in …
View article: Insights into the Inhibitory Activity and Mechanism of Natural Compounds from Rhinacanthus Nasutus on Α-Glucosidase Through Kinetic, Molecular Docking, and Molecular Dynamics Studies
Insights into the Inhibitory Activity and Mechanism of Natural Compounds from Rhinacanthus Nasutus on Α-Glucosidase Through Kinetic, Molecular Docking, and Molecular Dynamics Studies Open
View article: LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study Open
View article: Distress and its Correlation with Potential Factors among Patients with Cancer in Vietnam
Distress and its Correlation with Potential Factors among Patients with Cancer in Vietnam Open
A cancer diagnosis and treatment are stressful for patients. Evidence has shown that the prevalence of mental health problems among cancer patients is very high globally. To our knowledge, there are no studies related to cancer diagnosis a…
View article: Isolation, anticancer potency and camptothecin – producing ability of endophytic fungi isolated from Ixora chinensis
Isolation, anticancer potency and camptothecin – producing ability of endophytic fungi isolated from Ixora chinensis Open
Purpose Camptothecin (CPT) is an important alkaloid used for anticancer treatment. It is mainly produced by two endangered and overharvested Camptotheca acuminata and Nothapodytes nimmoniana plants. Endophytic fungi are promising alternati…
View article: Supplementary Figure 1 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
Supplementary Figure 1 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer Open
Supplementary Figure 1: Consort